Ocutrx

Overview
News
Extended Reality?
Product stageSegments
Go-to-Market
?
Hardware manufacturers
?

Ocutrx specializes in the creation of AR headsets for medical purposes, targeted toward users with moderate to severe age-related macular degeneration (AMD) and low vision centers as well as retinal surgeons. The company announced its Oculenz AR headset in January 2024, retailing at USD 6,000. Key features include a 2.5K per eye resolution with a 72° field of view (FOV), and the headset is powered by Qualcomm’s Snapdragon XR2 processor. The company also has a patented interpupillary distance adjustment to prevent dizziness. Further, Ocutrx’s software development kit (SDK) extends the OcuLenz use to fields such as the military and enterprise sectors.

The headset enables users suffering from AMD to engage in activities such as reading books and newspapers, playing cards, watching television shows and movies, and enjoying daily activities. The ORLenz, launched in October 2019, is a 4K VR headset that displays 3D holographic images with a 120-degree FOV and a resolution of 60 pixels-per-degree, providing 6 DoF tracking, allowing surgeons, techs, and students freedom of movement and positioning during surgeries. The headset is wireless and tetherless, weighing ~250 grams, and utilizes the company’s patented WiDtrix technology, which allows the headset to receive 3D surgical data with near-zero latency alongside integration with 5G Edge technology. Furthermore, the ORLenz is equipped with a MedTiles subsystem that overlays vital surgery information in an AR FOV, which can be accessed by voice command or posed in a "horizon" view. In January 2024, the company also announced the DigiLoupe AR/XR headset, a digital loupe version of its ORLenz headset.

Other products produced by Ocutrx include its OR-Bot, a collection of Ocutrx products that operates within a 3D pipeline, CamTrx a digital microscope, MiniLenz, a digital viewport for surgeons, and SteroLenz, a 3D Monitor that functions without the need to wear polarized 3D glasses. As of January 2024, Ocutrx held 16 patents covering its multiple medical and “OR” product portfolios.

In April 2023 , the company acquired electronics manufacturing and assembly company Spectrum Advanced Manufacturing Technologies to leverage control over its supply chain and use Spectrum’s infrastructure to manufacture the OcuLenz while adhering to FDA regulations within the US.

HQ location:
Irvine CA USA
Founded year:
2015
Employees:
101-250
IPO status:
Private
Total funding:
-
Last Funding:
-
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.